Natriuretic peptides, heart failure and LCZ696 (Entresto®)

Both BNP and NT-proBNP are considered to be gold standard biomarkers of HF. Both of these are also incorporated into the majority of the national and international cardiovascular therapy guidelines. However, despite this, our understanding of their very complex nature is still far from being complete and comprehensive. Moreover, the constant development of new approaches in patient care and the implementation of new therapeutic agents generate new questions and challenges for the use of NPs for HF diagnostics and the monitoring of HF therapy.